clinical trials patient recruitment

Many companies have launched successful exploratory and investigative clinical trials targeting oncology.  Clinicaltrials.gov lists 24,710 active cancer trials during the past 10 years.  Specifically, 1,763 non-small cell lung cancer trials were conducted over...

Celgene Corp. recently released positive Phase 3 data for its cancer drug Abraxane in combination with gemcitabine (Lilly’s chemotherapy drug) for the treatment of advanced pancreatic cancer.  The Abraxane study, nicknamed MPACT (Metastatic Pancreatic Adenocarcinoma...

Portland, Oregon-based Galena Biopharmaceuticals has begun recruiting breast cancer patients for its Phase III PRESENT (Prevention of Recurrence in Early-Stage Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) trial. ...

When planning Phase 1 trials, there are many high profile cost-drivers — from patient recruitment to CRO contracting.  For many therapeutic areas, these functions will require the most money and time on the part of the clinical trial team.  However, for the...

The pharmaceutical industry is feverishly searching for the next big drug to replace lost revenue from patent expirations on major blockbuster medicines.  Drugs with more than $30 billion in annual revenue lost patent protection in the last two years.  Patent...

Finding patients in a very specific disease state is difficult enough, but in the shadow of Phase III, it’s nearly impossible.  In fact, next to Phase IV, Phase III patient enrollment looks easy.  Phase IV patient recruiters are stuck competing not only with...

The drug industry’s reliance on companion diagnostics (CDx), particularly among large companies, has grown in recent years. According to the BasePair Group, CDx Partnerships with pharma have more than doubled between 2011 and 2012. Cutting Edge Information found...

Phase 4 clinical trials not only serve to gather valuable data surrounding drugs’ safety, tolerability and real-time effectiveness, but also to test potential new indications, develop stronger marketing profiles, gain payers’ favor and prove superiority over...

By Shaylyn Pike,Senior Research Analyst The emerging markets are not the United States, nor are they the European Union. It seems like a simple statement, but in Cutting Edge Information's latest research on clinical development in the emerging markets,...

By Shaylyn Pike,Senior Research Analyst Russia's Association of Clinical Trials Organization (ACTO) recently released its Q3 newsletter, and the outlook does not look promising for clinical development in the country. The drug industry in Russia has suffered...